These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 34608555)

  • 1. Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma.
    Ishido K; Kimura N; Wakiya T; Nagase H; Hara Y; Kanda T; Fujita H; Hakamada K
    Ann Surg Oncol; 2022 Feb; 29(2):1281-1293. PubMed ID: 34608555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new scoring system with simple preoperative parameters as predictors of early recurrence of pancreatic ductal adenocarcinoma.
    Shimagaki T; Sugimachi K; Mano Y; Tomino T; Onishi E; Nakashima Y; Sugiyama M; Yamamoto M; Morita M; Shimokawa M; Yoshizumi T; Toh Y
    PLoS One; 2023; 18(7):e0288033. PubMed ID: 37450554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel combined carbohydrate antigen 19-9 and lymphocyte-to-monocyte ratio score can predict early recurrence of resectable pancreatic ductal adenocarcinoma.
    Yugawa K; Maeda T; Nagata S; Sakai A; Taketani K; Yamaguchi S; Konishi K; Hashimoto K
    Surg Today; 2023 Oct; 53(10):1199-1208. PubMed ID: 36943449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study.
    Matsumoto I; Murakami Y; Shinzeki M; Asari S; Goto T; Tani M; Motoi F; Uemura K; Sho M; Satoi S; Honda G; Yamaue H; Unno M; Akahori T; Kwon AH; Kurata M; Ajiki T; Fukumoto T; Ku Y
    Pancreatology; 2015; 15(6):674-80. PubMed ID: 26467797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
    Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
    World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
    Kim NH; Kim HJ
    Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9.
    Li D; Peng Q; Wang L; Cai W; Liang M; Liu S; Ma X; Zhao X
    Eur Radiol; 2024 Jan; 34(1):509-524. PubMed ID: 37507611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
    Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
    Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
    Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
    Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
    Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting Recurrence-Free Survival After Upfront Surgery in Resectable Pancreatic Ductal Adenocarcinoma: A Preoperative Risk Score Based on CA 19-9, CT, and
    Jeong B; Oh M; Lee SS; Kim N; Kim JS; Lee W; Kim SC; Kim HJ; Kim JH; Byun JH
    Korean J Radiol; 2024 Jul; 25(7):644-655. PubMed ID: 38942458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
    Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
    Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative predictors for early recurrence of resectable pancreatic cancer.
    Nishio K; Kimura K; Amano R; Yamazoe S; Ohrira G; Nakata B; Hirakawa K; Ohira M
    World J Surg Oncol; 2017 Jan; 15(1):16. PubMed ID: 28069033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma.
    Sugiura T; Uesaka K; Kanemoto H; Mizuno T; Sasaki K; Furukawa H; Matsunaga K; Maeda A
    J Gastrointest Surg; 2012 May; 16(5):977-85. PubMed ID: 22411488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection.
    van Oosten AF; Groot VP; Dorland G; Burkhart RA; Wolfgang CL; van Santvoort HC; He J; Molenaar IQ; Daamen LA
    Ann Surg; 2024 Mar; 279(3):493-500. PubMed ID: 37389896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
    Chen T; Zhang MG; Yu XJ; Liu L
    Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel online calculator to predict early recurrence and long-term survival of patients with resectable pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: A multicenter study.
    Zhang XP; Gao YX; Xu S; Zhao GD; Hu MG; Tan XL; Zhao ZM; Liu R
    Int J Surg; 2022 Oct; 106():106891. PubMed ID: 36165934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiographic duodenal invasion is associated with poor prognosis and early recurrence in patients with pancreatic ductal adenocarcinoma.
    Miyazawa M; Hirono S; Kawai M; Okada KI; Kitahata Y; Motobayashi H; Sato M; Yoshimura T; Ueno M; Hayami S; Miyamoto A; Shimizu A; Yamaue H
    Eur J Surg Oncol; 2023 Oct; 49(10):106960. PubMed ID: 37353425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
    Scand J Gastroenterol; 2019 Jun; 54(6):780-786. PubMed ID: 31180790
    [No Abstract]   [Full Text] [Related]  

  • 20. Preoperative carbohydrate antigen 19-9 and standard uptake value of positron emission tomography-computed tomography as prognostic markers in patients with pancreatic ductal adenocarcinoma.
    Moon D; Kim H; Han Y; Byun Y; Choi Y; Kang J; Kwon W; Jang JY
    J Hepatobiliary Pancreat Sci; 2022 Oct; 29(10):1133-1141. PubMed ID: 33063453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.